company-header-logo-avalon

Avalon GloboCare Corp.

Avalon GloboCare Corp. (Nasdaq: AVCO) is a clinical-stage biotechnology company dedicated to develop and deliver innovative and transformative CellTech with multifunctional convergence in cellular technologies/therapeutics, precision diagnostics and intellectual property in the field of immuno-oncology and cellular medicines.

Nasdaq: AVCO
IR Website: https://ir.avalon-globocare.com/
Headquarters: Freehold, NJ

The company’s core technology platforms include cellular therapies (CAR-T, CAR-NK, mRNA-based Flash-CARTM), Avalon clinical-grade tissue-specific exosomes (ACTEXTM), and precision companion diagnostics related to cellular medicines.

TALK TO MANAGEMENT

The Avalon Globocare management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Summary

Press Releases

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

Video: Bezinga Presents an Interview with Avalon GloboCare

CAR-T Cells and Their Transformational Promise

CAR-T Market Size

Exosomes - What Are They and How is AVCO Using Them?

Regenerative Therapy Market

Current Candidates

Strategic Partnerships

Financials

SEC Filings

Board of Directors and Advisory Board

Senior Management Bios

Risks & Disclosures

avalon-logo-white

The Avalon GloboCare Corp. management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the Avalon GloboCare Corp. story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.